http://www.futureprescriber.co.uk Future Prescriber EarlyView RSS Feed http://www.futureprescriber.co.uk/details/journalArticle/1435657/Dapagliflozin_a_new_possibility_for_managing_type_2_diabetes.html Abstract Dapagliflozin is a new sodium‐glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd. 2012-01-03T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1435659/Promising_developments_in_the_treatment_of_cancer.html Abstract The latest developments in the treatment of cancer were presented in September at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden Copyright © 2011 John Wiley & Sons, Ltd. 2012-01-03T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1435661/Asenapine_novel_antipsychotic_for_treatment_of_bipolar_I_disorder.html Abstract Asenapine is a new antipsychotic agent with activity for multiple receptors. It is administered sublingually for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. In this Drug profile the authors review the pharmacodynamic and pharmacokinetic properties of asenapine, and discuss its efficacy in bipolar I disorder and its likely positioning in clinical practice.... 2012-01-03T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1435663/Immunotherapy_for_treatment_of_advanced_prostate_cancer.html Abstract Prostate cancer is the most common cancer in men. Up to 30% of affected men will experience disease recurrence at some point, most of whom will be treated with hormone ablative therapy, which is effective for up to 90%. However, the effect is transient with the emergence of the castration‐resistant phenotype. While secondary hormonal manipulations may result in temporary inhibition of disease progression,... 2012-01-03T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1385115/Promising_new_inotropes_for_the_treatment_of_heart_failure.html Abstract Positive news on the development of second‐generation inotropes for treating heart failure was reported at the annual British Cardiovascular Society conference in June. Copyright © 2011 John Wiley & Sons, Ltd. 2011-10-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1385117/NSCLC_novel_targeted_therapies_offer_hope_for_the_future.html Abstract Lung cancer remains a major healthcare challenge despite the recent reduction in incidence in the Western world and introduction of the public smoking ban in some countries. However, the complexity of tumour biology is being unravelled along with a greater understanding of molecular signalling pathways, opening up a new field of research into targeted therapies. Here the authors focus on non‐small cell lung cancer... 2011-10-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1385119/Telaprevir_new_specific_protease_inhibitor_for_chronic_hepatitis_C.html Abstract Current treatment for hepatitis C virus (HCV) genotype 1 infection with pegylated interferon (PEG‐IFN) and ribavirin (RBV) is effective in less than 50% of patients. Retreatment with the same regimen is poorly effective. The advent of direct‐acting antiviral agents that target replication of HCV promises to improve therapy for the disease. Telaprevir is a new protease inhibitor that specifically targets the NS3/4A... 2011-10-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1385121/Bipolar_I_disorder_current_and_future_management_options.html Abstract Bipolar I disorder affects around one in every 100 adults and is a major public health issue. It is usually characterised by a combination of manic and depressive symptoms, with severe episodes of mood disturbance that can last for weeks or even months. Both men and women are affected, and the condition is a debilitating one that can adversely influence all areas of a person's life and his/her normal functioning.... 2011-10-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1311527/Novel_GLP1_mimetics_in_diabetes_lixisenatide_and_albiglutide.html Abstract Lixisenatide and albiglutide are glucagon‐like peptide‐1 (GLP‐1) agonists in clinical development that are similar to exenatide and liraglutide. This review critically considers the emerging evidence on the pharmacology, efficacy, safety and potential roles these two agents may have in clinical practice. 2011-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1311531/Raising_HDLC_through_cholesteryl_ester_transfer_protein_inhibition.html Abstract Plasma concentrations of high‐density lipoprotein cholesterol (HDL‐C) and its major protein component apolipoprotein (apo) A‐I are strongly inversely correlated with cardiovascular risk, leading to the notion that therapy to increase HDL‐C and apoA‐I concentrations would be antiatherosclerotic and protective against cardiovascular disease (CVD) events.1,2 In this article, the authors discuss how inhibition of... 2011-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1311529/Lundbeck_leading_the_way_in_the_treatment_of_CNS_disorders.html Abstract This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Lundbeck and its current portfolio, and look at its pipeline of new drugs and areas of research interest. 2011-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1073499/Saxagliptin_for_patients_with_T2D_and_renal_impairment.html Abstract Saxagliptin (Onglyza) now offers a further treatment option for patients with type 2 diabetes and moderate to severe renal impairment, improving glycaemic control compared with placebo with a favourable tolerability profile. 2011-05-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1073497/Ticagrelor_new_antiplatelet_for_prevention_of_thrombotic_events.html Abstract Antiplatelet drugs such as aspirin and clopidogrel are the cornerstone of atherothrombotic prevention in patients with ACS following percutaneous coronary intervention and coronary artery bypass grafting. However, due to variable response with these drugs many patients still experience atherothrombotic complications despite treatment. Ticagrelor (Brilique) reversibly and selectively inhibits adenosine... 2011-05-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1073503/Boehringer_Ingelheim_a_new_commitment_to_diabetes.html Abstract This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its recent strategic alliance with Eli Lilly & Co to develop new treatments for diabetes, a... 2011-05-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1073501/Fingolimod_new_oral_treatment_for_multiple_sclerosis.html Abstract Fingolimod, a sphingosine‐1‐phosphate receptor modulator, is a novel oral treatment for multiple sclerosis. In this Drug profile the author reviews its mode of action, likely positioning and the advantages that it might offer in terms of clinical management of multiple sclerosis, and begins by setting the treatment context. 2011-05-31T00:00:00Z